LinkedIn This is a reminder that on November 08, Harish jakkamsetti sent you an invitation to become part of their professional network at LinkedIn. Your invitation will expire soon! Follow this link to accept Harish jakkamsetti's invitation. https://www.linkedin.com/e/isd/847228016/JolvSuHK/ Signing up is free and takes less than a minute. This is a reminder that on November 08, Harish jakkamsetti sent you an invitation to become part of their professional network at LinkedIn.
> To: [harish_bobby.bsecom@blogger.com]
> From: Harish jakkamsetti [harishrulezz@gmail.com]
> Subject: Harish jakkamsetti wants to stay in touch on LinkedIn
> I'd like to add you to my professional network on LinkedIn.
>
> - Harish jakkamsetti
The only way to get access to Harish jakkamsetti's professional network is through the following link: https://www.linkedin.com/e/isd/847228016/JolvSuHK/ You can remove yourself from Harish jakkamsetti's network at any time.
--------------
The pending expiration of your invitation is an automatic process triggered by system maintenance. This is the last email message you will receive from LinkedIn about the expiration of this invitation from Harish jakkamsetti. © 2009, LinkedIn Corporation
Posted by
stockguru
at
9:10 AM
ho we are and what we do
Bosch India is regional branch of the Bosch Group, one of the world’s biggest private industrial corporations. Headquartered in Stuttgart, Germany, the Bosch Group has approx. 251,000 employees worldwide, and generated an annual sales revenue of 41.5 billion euros in 2005. |
|
 In India, the Bosch Group has about 15,044 employees, and in business year 2005 achieved total consolidated sales of Rs 40 billion (Euro 729 Mio). Bosch has grown phenomenally in India, way back since 1922 when the Illies company established a Bosch agency in British India. The founding of Motor Industries Company Limited in 1951 spurred off an accelerated growth in the automotive industry segment which has not stopped till date. Bosch has a strong and voracious presence in the country today, in diverse industry segments at numerous locations. In India, Bosch is represented in by its subsidiary companies - 1) Motor Industries Company Limited - MICO
2) Robert Bosch India Limited – RBIN
3) Bosch Rexroth India Limited – BRIN
4) Bosch Chassis System India Limited
| Automotive technologyBosch Group was the world's largest automotive supplier in terms of sales in 2004, generating a total of 25.3 billion euros. Bosch plans to utilize the opportunities in the rapidly growing Indian market for passenger cars. It is also stepping up its diesel operations in India, foraying into the manufacturing of common-rail diesel injector systems. In India, Automotive Technology represents the largest area of business, supplying both to the local automotive industry as well as exporting components around the world.
|
| Consumer goods and building technologyIn India, this sector is engaged in the Power Tools and Security Systems divisions. Bosch is the world leader in the power tools segment and has been the pioneer in DIY (Do-it-Yourself) across different countries, including India. Bosch Security Systems globally has more than 80 years of experience in fire detection and alarm systems. In India, Bosch Security Systems is one of the leading security technology players with a comprehensive portfolio.
|
| Industrial technologyBosch Rexroth AG is an expert for all drive, control and motion technologies. The Industrial Technology division Bosch Rexroth India provides a complete range of world-class products, systems and services to customers in India, Bangladesh, Nepal and Sri Lanka through its manufacturing facilities, service centres, and service partners from all over South Asia.
|
| Engineering and IT ServicesRobert Bosch India Limited is a 100% owned subsidiary of Robert Bosch GmbH, with over 3600 associates. We provide engineering, IT and business services for automotive, industrial, consumer goods and building technology, such as Process Consulting, Mechanical and Electronic Engineering, VLSI Services, Shared Services Accounting, and Translation/Documentation. We are ISO 9001:2000 certified and appraised at CMMI Level 5. We have development locations in Bangalore and Coimbatore. |
| Motor Industries Co. Ltd.,
Post Box No. 3000, Hosur Road,
Bangalore - 560 030,
Ph: +91-80-22220088 / 22992111. Fax: +91-80- 22272728 |
| Contact Details for Robert Bosch India Limited |
Robert Bosch India Limited
123 Industrial Estate, Hosur Road
Koramangala, Bangalore 560 095 Tel: +91-80-6657 5757
Fax: +91-80-6657 1404 |
| Contact Details for Robert Bosch India Limited Media |
| Ph: +91 - 080 - 5757 4545 |
| Contact Details for Bosch Rexroth India Limited |
Bosch Rexroth India Limited
Near Vatva Railway Station
Vatva
Ahmedabad – 382445
Tel: +91 - 079 - 2583 2837
Fax: +91 - 079 - 2583 2558 |
| Contact Details for Bosch Chassis System India Ltd |
Bosch Chassis System India Limited
Aurora Towers
4th floor
9, Moledina road
Pune – 411001
Phone: + 91 - 20 - 3987 0300
Fax: +91 - 20 - 2613 3704 |
| The Car Multimedia Division
Robert Bosch Car Multimedia GmbH provides intelligent solutions that allow the flexible and efficient integration of entertainment, navigation, telematics, and driver assistance in the vehicle. In this context, information presentation and processing are becoming increasingly important. Driver information and assistance systems are developed to take issues such as growing customer interest in fuel consumption and emissions reduction into account. In-car infotainment architectures are becoming increasingly networked. The decisive question is how the vehicle and the driver (or passenger) interact, and via what channels. Optimizing the future of the mobile world is the task, and driving convenience is the goal. That's why Bosch Car Multimedia works continuously to make driving easier, more cost-effective, and safer, despite increasing complexity. |
|
Our core areas of competence include:- Radio, entertainment, navigation, and telematics systems
- System integration of complex, networked car multimedia systems
- Devices and systems for commercial vehicles
- Premium instrument clusters and head-up displays
- Innovative tuner technology
- Functional components
- Repair of automotive electronic components
| Bosch Ltd.,
SMC Dept,
Post Box No. 3000, Hosur Road,
Bangalore - 560 030.
Ph: +91-80-22992973. |
| The Drive and Control Technology division in India
Established in 1975, Bosch Rexroth India serves customers in India, Bangladesh, Nepal and Sri Lanka through manufacturing facilities and service centers in Ahmedabad and Bangalore, five direct sales offices, and 30 sales and service partners all over South Asia. |
|
Bosch Rexroth (India) Ltd., the Drive and Control Company, provides a complete range of world-class products, systems and services for drive and control technologies in various industries such as machine tool, press, plastic processing equipment, steel mill, civil engineering, materials handling, earthmoving and other mobile applications, printing and packaging equipment, textile machinery, factory automation, etc. | 
As one of the leading suppliers of packaging technology in the world and part of the Euro 41.5 Billion, Robert Bosch GmbH group, we seek to provide you complete packaging solutions. Bosch develops, designs and manufactures packaging technology for the food, pharmaceutical, industrial, chemical and cosmetics industries. The subsidiary in India brings the global expertise to manufacture Form, Fill and Seal Machines for the Indian market. Innovation is our key to success and this is reflected in the tailor-made solutions that we offer for the Packaging Industry. In addition, the world-class quality, reliability, performance and affordable pricing of our machines has made it the preferred choice for large businesses. |
Since inception in 1993, the Bosch Power Tool division in India has grown to become the market leader in power tools segment. With a complete range of power tools for construction, woodworking and metalworking industry, the division meets and fulfills the needs of professional users. Added to this the division also has cordless tools and supports its products with a comprehensive range of accessories. For the first time in India, we have introduced tools for DIY (Do-It-Yourself) enthusiasts as well. Always One Step Ahead
Technical advancement at Bosch Power Tools has clear objectives: to consistently develop new products, in order to make work easier for the professional and to increase his efficiency. Trendsetting developments for working on wood, metal, concrete and for cordless tools are now again setting new standards. See for yourself: with innovations from Bosch, you are always one step ahead. |
Fun, Simple & Easy!
Bosch ushers in a never before experience: The Do-It- Yourself experience. As one of the leading power tool manufacturers in the world, Bosch innovation and quality has filtered through, to create a whole range of DIY tools. Now you can experience the sheer joy of Do-It-Yourself with the IXO, SMARTKIT and AQUATAK. These home tools help you complete scores of jobs effortlessly and without depending upon anyone.
|
| IXO- CORDLESS SCREWDRIVER
Part No. :0 601 960 8KO
Screwdriver : 3 mm
Drill Dia. : 2 mm
Torque : 4 Nm
No-load Speed : 180 rpm
Battery Voltage : 3.6 V
Weight with Battery : 0.3 Kg
Applications
• Fixing back loose and worn out screws
• Fixing of knobs and handles in kitchens and baths
• Knocking down and completely setting up the furniture
• For dodgy windows, hanging boards and creaky cupboards
|
| SMARTKIT - MULTIPURPOSE TOOLKIT
Part No. : F 002 H92 40L
Bosch GSB 10RE Impact Drill & Drill Bit, Fischer Fixings, Claw Hammer, Adjustable Wrench, Hack Saw, Measuring Tape, Insulation Tape, Screws, Screwdriver Set (8 Pc.), Combination Plier, Carpenter's Pencil, Adjustable Knife, 6 Pc. Spanner Set (6 mm-17 mm)
Applications
• Enables drilling into wood, concrete and metal
• Put up your precious paintings, set right your furniture or simply work around your home
• Handy tools that help perform all types of restoration and repairing Jobs at your home
|
| AQUATAK 100 PLUS - HIGH PRESSURE WASHER
Part No. : 0 600 876 B00
Max. Pressure : 100 bar
Max. Flow Rate : 350 l/h
Max. Flow Temperature : 60° C
Motor Power : 1500 W
Hose Length : 5 Mts.
Auto stop : Yes
Weight : 6 Kg
Applications
• Washes your car squeaky clean, right from the wheels and doors to the most unreachable of areas
• Cleans the tiles in the garden paths and driveways
• Removes dirt that sticks to garage shutters, which is otherwise hard to clean
|
| |
|
|
|
| Anchor bolt FAZDescription
• Anchor bolt for push-through installation.
• When the hexagonal nut is tightened, the tapered bolt is pulled into the expansion clip and expands it against the drill hole wall. Advantages/Benefits
• Optimised expansion clip ensures uniform load distribution for high loads and small edge distances and axial spacings with filigree building components as well as secure expansion even in cracked concrete.
• Installation-friendly, since only a few revolutions are necessary to apply the torque.
|
| Anchor bolt setting tool FABS Description • Especially suitable for the efficient installation in series of larger numbers of fischer and Upat anchor bolts. • The tool is simply clamped into a standard SDS Plus hammer drill and is perfect for hammering the anchor into the hole. This greatly simplifies the installation process when working overhead. Advantages/Benefits
• Efficient installation of all fischer and Upat anchor bolts.
• Ergonomic design, saves time and energy.
• Universally usable for M 6 to M 12.
|
| |
|
|
|
|
|
Posted by
stockguru
at
9:01 AM
About Us
"Our ability to continuously scale new heights across the biopharmaceutical value chain enables us to realise the promise of future therapeutics." -Kiran Mazumdar-Shaw, Chairman & Managing Director
Biocon is a fully integrated healthcare company that delivers innovative biopharmaceutical solutions. From discovery to development and commericalisation, we have the defining science, cost-effective drug development capabilities and significant manufacturing capacity to move ideas to market. Leveraging India’s globally competitive cost base and exceptional scientific people resource, we are advancing our in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through our subsidiary companies, Syngene and Clinigene. Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and several other molecules at exciting stages in the biopharmaceutical value chain. With the successful commercial launch of our first anti-cancer drug and several promising discovery partnerships in the clinic, we remain committed to scaling new heights in frontier science and Businesses 
Click here to enlarge
Biocon’s fully integrated business model spans the entire drug value chain, from pre-clinical discovery to clinical development and through to commercialisation. Our businesses in custom research (Syngene), clinical development (Clinigene) and biopharmaceuticals (Biocon) provide multiple revenue streams to balance risk, drive innovation, deliver products and accelerate growth. As we increase the complexity and scope of our own R&D and manufacturing operations, especially in new product discovery and development, we believe our custom and clinical research services will continue to offer important synergies. Syngene : Pre-Clinical Discovery
Biocon’s custom research organisation, Syngene, offers high value discovery and development services, from target identification and validation to small molecule and library synthesis. With our reputation for meticulous IPR protection, we provide pharmaceutical and biotechnology majors customised solutions in the areas of synthetic chemistry and molecular biology. Clinigene : Clinical Development
Biocon’s clinical research organisation, Clinigene, specialises in Phase I-IV clinical trials and studies, using well-characterised clinical databases in diabetes, oncology, lipidemia and cardiovascular diseases. We offer these services at our CAP and NABL accredited Central Reference Laboratory and a state-of-the-art Bioavailability and Bioequivalence (BA/BE) Centre. Biocon : Commercialisation
Biocon has an impressive track record of commercialisation capabilities. We have brought to market a considerable portfolio of biopharmaceuticals, led by our blockbuster Statins. The commercialisation of Insulin, Immunossuppressants and a range of Biogenerics demonstrates our highly advanced process development and manufacturing expertise. Under rapid progress are two challenging collaborative projects for the development of novel medicine, including Oral Insulin and T1h. Biocon also markets a basket of branded formulations in India, among them INSUGEN®, BIOMAb EGFR™ and EPO.| | Key Facts
General Information
Biocon Limited is a fully integrated biopharmaceutical company focused on biopharmaceuticals, custom research and clinical research.Subsidiary Companies:
Syngene International Limited is a custom research organisation offering synthetic chemistry and molecular biology services for early stage drug discovery and development.
Clinigene International Limited is a clinical research organisation offering Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors. Biocon Biopharmaceuticals Private Limited (BBPL) is a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines.
Intellectual Profile of 3500 Personnel
Biocon, Syngene and Clinigene together employee approximately 3500 qualified personnel - from biologists, chemists, medical practitioners, pharmacologists, engineers, finance / legal / marketing analysts, HR generalists to general administrators. 5% of our employees hold PhD degrees, 40% have a masters degree in science and the remaining are graduates with a bachelors degree in science, commerce or arts. 15% of Biocon employees are women(across the group). The employee attrition last quarter was 4% and last year it was over 20%. The average age of the employee is 28.8.
Milestones
- Biocon is India's first biotechnology company, established
in 1978
- Biocon is India's first biotechnology company to export
microbial enzymes to USA and Europe
- Biocon is the first biotechnology company to receive ISO
9001 certification in India
- Syngene, a Biocon subsidiary, is India's first custom
research company in drug discovery
- Biocon is the first Indian company to be approved by
US FDA for the manufacture of lovastatin, a
cholesterol-lowering molecule
- Biocon's proprietary bioreactor, the PlaFractor™, receives a US patent
- Biocon's subsidiary, Clinigene, has India's first CAP
(College of American Pathologists) accredited clinical
research laboratory, setting the benchmark for
laboratories in India
- Biocon is awarded the Biotech Product and Process
Development and Commercialisation Award, 2001 by
the Department of Biotechnology, Ministry of Science
and Technology, Government of India
- Syngene is awarded the Certificate of Excellence for
Export Achievement by the Government of India, for
two consecutive years 2002-2003
- Biocon is the first company, globally to manufacture
human insulin, INSUGEN®, using a Pichia expression
system, 2004
- Biocon launches BIOMAb EGFR™ India's first anti-cancer, therapeutic Monoclonal Antibody-based drug for treating solid tumors of epithelial origin, such as head & neck cancers, 2006
- Biocon divests its enzymes division to Novozymes, focuses on biopharmaceuticals, 2007
- Syngene receives "BioServices Company of the Year",
BioSpectrum Awards, 2007
- Biocon's BIOMAb EGFR™ wins "Product of the Year",
BioSpectrum Awards, 2007
- Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30
Million, 2008
ProductsBiopharmaceuticals Active Pharmaceutical Ingredients (APIs) - Anti-Diabetic Agents
- Anti-Inflammatory Agents
- Anti-Oxidants
- Cardiovascular Agents
- Anti-Obesity Agents
- Digestive-Aid Enzymes
- Anti-Hypertensive Agents
- Haemostatic Agents
- Hepatoprotective Agents
- Immunosuppressants
- Gastro-Intestinal Agents
- Nutraceuticals
Biologicals - Insulin
- Streptokinase
- EPO
- GCSF
- Monoclonal Antibodies
Branded Formulations Oncology - BIOMAb EGFR™
- NUFIL™ (Pre-filled Syringe)
- Abraxane® for injectable suspension
Nephrology - ERYPRO safe (Pre-filled Syringe)
- TACROGRAF
- RAPACAN
- CYCLOPHIL ME
- RENODAPT
- RENODAPT - S Cardiology - STATIX
- STATIX-F
- STATIX-EZ
- CLASPRIN
- TELMISAT
- TELMISAT H
- ZARGO
- ZARGO H
- ZIGPRIL Diabetology - BLISTO 1 & 2
- BLISTO MF 1 & 2
- PIODART
- PIODART MF
- GABIL
- METADOZE IPR
- TRIGPM
- GMAB PLUS
- ZUKER – MF
- OLISAT
- INSUGEN 30/70
- INSUGEN 50/50
- INSUGEN R
- INSUGEN N
Dosage Forms Biocon offers Indian pharmaceutical companies finished dosage formulations in the categories of cardiology, diabetology, nephrology, oncology and other specialised therapeutic segments. We provide formulations in the form of tablets, capsules, injections, liquid-orals and pellets.
Services
Licensing
Biocon collaboratively develops MAbs (Monoclonal Antibodies) and other novel drug delivery systems-based proteins either in-house or in partnership with other companies.
Contract Manufacturing
Biocon leverages its India cost base together with its extensive expertise and technology platforms to offer competitive, high quality, custom manufacturing services to a global clientele.
Research Services
| Custom Research - Syngene |
Chemistry
- Medicinal Chemistry
- Library Synthesis
- Process R&D
- Custom Manufacturing
- Analytical Services
- Polymer Chemistry
|
Biology
- Molecular Biology
- Protein Sciences
- Cell Lines Services
- Assay Services
- eADME/T&PK Studies
- Biologics
| | | | Clinical Research -Clinigene | - Clinical Operations
- Clinical Development
- Clinical Data Management and Biostatistics
- Regulatory Services
- Human Pharmacology unit
- Bioanalytical Research Laboratory
- Central Laboratory
|
Contact
Corporate Headquarters20th KM Hosur Road
Electronics City
Bangalore 560 100
India
Phone: 91 80 2808 2808
Fax: 91 80 2852 3423
Email: contact.us@biocon.com Overseas Representative Office New Jersey
485 Route 1 South
Woodbridge Corporate Plaza
Building B Suite 305 lselin,
NJ 08830, USA
Phone: 732 636 2950
Fax: 732 636 2951
Email: abhijit.zutshi@biocon.com London
Biocon Limited
50, Elm Quay Court
30, Nine Elms Lane
SW8 5DF, London
Phone : +44 2078199788
Fax : +44 2074502980
Mobile : +44 7515962466
Email: nehal.vora@biocon.com Abu Dhabi
NeoBiocon
P.O. Box 72900
Abu Dhabi
United Arab Emirates
Phone: +971-2-550 1000
Fax: +971 -2- 550 1199
Mobile: +971 50 5826489
Email: sumit.bhanot@biocon.com Human Resources For careers at Biocon, please contact us at:
Phone: 91 80 2808 2808
Email: human.resources@biocon.com Licensing/ Collaboration Opportunities To submit licensing/collaboration opportunities
enquiries, please contact:
Mr. Sandeep Rao
General Manager - Business Development
Phone: 91 80 2808 2070
Email: sandeep.rao@biocon.com Investor Relations For investor related queries please contact:
Mr. Kiran Kumar
Company Secretary
Phone: 91 80 2808 2037
Email: investor.relations@biocon.com Corporate CommunicationsFor media related queries, please contact:
Ms. Paula Sengupta
Head - Corporate Communications
Phone: 91 80 2808 2808
Email: corporate.communications@biocon.com |
| | | | Mission
To be an integrated biotechnology enterprise of global distinction.
Essential to this mission is excellence in: - Intellectual asset creation through discovery, research
and development
- State-of-the-art manufacturing capabilities
- Internationally benchmarked quality and regulatory systems
- New medical insight through disease specific
clinical research
- Customer relationship through outstanding products
and services
- Human resource development through training,
mentoring and empowering
- Management of research and business partnerships |
| | | | | People
An organisation is as dynamic and effective as its people. At Biocon, the vast experience of our distinguished Board of Directors, the invaluable learning of the Scientific Advisory Board and the strategic focus of the Key Management Team steer us towards our goals. They are amply supported by a 3000-strong team of exemplary bioscientists, engineers and business managers who build our intellectual capital and drive our growth.The Board of Directors determines strategic business imperatives and mentors the achievement of our corporate goals.
The Scientific Advisory Board ensures that we meet global benchmarks in the realm of biotechnology. To accomplish this, it advises the organisation on various research programmes, evaluates the intellectual property generated and identifies research partnerships.
The Key Management Team focuses on driving innovative work practices and higher process maturity across the organisation. It executes its role in corporate governance through regular reviews of our financial performance and critical business issues. | | | | |
| | People
Board of Directors Dr. Neville Bain
|  | - Chairman, Institute of Directors, UK
- Board Member, Scottish & Newcastle
Plc., Provexis Ltd.
- Former Group CEO, Coats Viyella Plc.
- Former Deputy Group Chief Executive
and Finance Director, Cadbury
Schweppes Plc.
- Author of several management books
on corporate governance, strategy
and people management
| Prof. Charles L. Cooney
|  | - Professor, Chemical & Biochemical
Engineering, MIT, USA
- Director, Genzyme Inc. and
Bio-Processors Inc.
- Recipient of prestigious awards,
including Gold Medal of the Institute
of Biotechnology Studies and
Distinguished Service Award
from the American Chemical Society
| Dr. Bala S. Manian
|  | - Chairman and Founder, Reametrix Inc.
- Co-founder, Quantum Dot Corporation
and Surromed Corporation, USA
- Expert in the design of electro-optical
systems
- Authored several peer-reviewed
scientific publications and holder of
many patents
- Recognised through numerous
awards for contributions as educator,
inventor and entrepreneur, including
Technical Academy Award in Digital
Cinematography by Academy of
Motion Pictures, Arts and Sciences
| Mr. Suresh Talwar
|  | - Partner, Talwar Thakore & Associates
- Director, Cadbury India Ltd., Birla
Sun Life Insurance Co. Ltd., L&T Ltd.
- Area of professional specialisation
includes corporate law and related fields
- Legal counsel to numerous Indian
companies, multinational corporations
and Indian/foreign banks
| Ms. Kiran Mazumdar-Shaw
|  | - Chairman & Managing Director, Biocon
- First generation entrepreneur with
more than 29 years experience
in biotechnology and industrial enzymes
- Master Brewer, Ballarat University,
Australia
- Awarded the Padmabhushan, one of
India’s highest civilian awards for
her pioneering efforts in
Biotechnology, 2005
| Mr. John Shaw
|  | - Vice Chaiman, Biocon
- Served in senior corporate positions
at various locations around the world
- Chairman, Madura Coats Ltd.
between 1991-1998
| Prof. Ravi Mazumdar
|  | - University Research Chair Professor,
Department of Electrical and
Computer Engineering, University
of Waterloo, Canada
- Fellow of the Institute of Electrical
and Electronics Engineers (IEEE) and
Fellow of the Royal Statistical Society
| Prof. Catherine Rosenberg
|  | - Alternate Director, Biocon
- University Research Chair Professor
and Chairman, Department of
Electrical and Computer Engineering,
University of Waterloo, Canada |
| | People
Scientific Advisory Board Prof. Charles L. Cooney
| 
| - Chairman, Scientific Advisory Board, Biocon
- Head of Chemical & Biochemical Engineering, Massachusetts Institute of Technology, USA | Dr. Anthony Allison
| 
| - Distinguished Scientist,
Surromed Corporation
- Former Vice President, Research,
Syntex Corporation-Inventor of
Mycophenolate Mofetil
| Prof. Hans Wigzell
| 
| - Director-General, Swedish Institute for Infectious Diseases
- President, Karolinska Institute, Sweden
| Dr. Chaitanya R. Divgi
| 
| - Chief, Nuclear Medicine & Clinical Molecular Imaging, University of Pennsylvania, USA
| Dr. Bala S. Manian
| 
| - Chairman & Founder Reametrix Inc.,
Co-founder Quantum Dot Corporation
and Surromed Corporation, USA
| Ms. Kiran Mazumdar-Shaw
| 
| - Member of the Board, Science Foundation, Ireland Chairperson, Vision Group on Biotechnology, Government of Karnataka
- Chairperson, National Task Force on Biotechnology, CII
| Mr. Shrikumar Suryanarayan
| 
| - Former President of Research and Development, Biocon Limited
- Visiting faculty, Karolinska Institute, Sweden
|
| | | | Quality
Biocon follows good manufacturing, laboratory and documentation practices that ensure consistent high quality results. Our state-of-the-art analytical facilities monitor and maintain strict quality of our products, processes and services, consistently meeting EDQM, USP and other national and international quality standards. Biocon's quality chain covers three key functional areas: - Quality Control
- Quality Assurance
- Regulatory Affairs Quality Control (QC) is responsible for all analyses undertaken at Biocon. From analytical support during product development and validations to training Biocon customers, QC is supported by a highly qualified team of professionals. Quality Assurance (QA) comprises of Corporate QA and
Site QA. - Site QA is responsible for implementation of quality
systems and release of all manufactured products.
- Corporate QA develops and ensures harmonisation of
all systems throughout the organisation. It is also
responsible for all audits including regulatory (national
and international), customer, GMP, GLP and GCP. Regulatory Affairs ensures compliance with the requirements of national and international regulatory authorities.ality
Accreditations & Approvals
International Quality Accreditations
Biocon
- Received ISO 9001 accreditation in 1993
- Implemented an integrated Environment, Health and
Safety management system
- ISO 14001:2004 certified
- OHSAS 18001:1999 certified
Syngene
- ISO 9001:2000 certified
Clingene's Clinical Research Laboratory
- The first in India to be CAP (College of American
Pathologists) and NABL (National Accreditation Board
for Testing and Calibration Laboratories) accredited.
- ISO 15189:2003 accredited for quality and competence.
Facility Approvals
- US FDA approved Biocon Campus and the additional
facilities at Biocon Park in December 2006.
- EU GMP Certification for Biocon Campus in 2004 and 2005.
The 2006 EU GMP inspection covered the additional facilities
at Biocon Park.
- Biocon has received a number of CoPP (Certificate of a Pharmaceutical Product) certificates.
- WHO GMP certification for the facilities at Biocon Campus
and Biocon Park.
- EDQM (European Directorate for Quality of Medicines)
granted Certificate of Suitability (COS) for a number
of products manufactured at both, Biocon Campus
and Biocon Park.
- The Mexican Health Authorities inspected and accepted
both, Biocon Campus and Biocon Park, in 2006
- The Cuban National Regulatory Authority (CECEMED)
inspected and accepted the facilities at Biocon Campus
and Biocon Biopharmaceuticals Pvt. Ltd. (BBPL) in 2007.
- Ministry of Health at United Arab Emirates has granted facility approval for both Biocon Campus and Biocon Park, in 2007
- Products from Biocon Biopharmaceuticals have been approved in Uruguay, Thailand, Ukraine and Chile |
|
Quality
Quality Commitment
- To maintain the highest quality standards for all Biocon
products
- To develop novel analytical methods for new products
- To maintain and monitor quality systems within Biocon,
Syngene, Clinigene and BBPL according to national
and international quality standards.
- To register Biocon's drug products in many more
regulated markets.
- To file regulatory dossiers for new products
- To ensure personnel validation through training and
evaluation
- To support customers with their technical and regulatory
queries
| |
November 29, 1978
Biocon’s Founding Day - the start of a biorevolution in India. Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated biopharmaceutical enterprise. Today, we leverage a formidable combination of proprietary fermentation technologies and research skills to develop affordable therapy for unmet medical needs
Biocon India is incorporated as a joint venture between Biocon Biochemicals Ltd. of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw
1979
Biocon is the first Indian company to manufacture and export enzymes to USA and Europe
1989
Unilever plc. acquires Biocon Biochemicals Ltd. in Ireland and merges it with its subsidiary, Quest International
Biocon is the first Indian biotech company to receive US funding for proprietary technologies
1990
Biocon scales up its in-house research programme, based on a proprietary solid substrate fermentation technology, from pilot to plant level
1993
Biocon's R&D and manufacturing facilities receive ISO 9001 certification from RWTUV, Germany
1994
Biocon establishes Syngene International Pvt. Ltd. as a Custom research Company (CRC) to address the growing need for outsourced R&D in the pharmaceutical sector
1996
The commercial success of Biocon's proprietary fermentation plant leads to a 3-fold expansion
Biocon leverages its technology platform to enter biopharmaceuticals and statins
1997
Biocon spearheads initiatives in human healthcare through a dedicated manufacturing facility
1998
Unilever inks a deal with ICI to sell its specialty chemicals division of which Quest International is a part. Unilever agrees to sell its shareholding in Biocon to the Indian promoters. Biocon becomes an independent entity
2000
Biocon commissions its first fully automated submerged fermentation plant to produce specialty pharmaceuticals
Biocon establishes Clinigene, India's first Clinical Research Organisation (CRO) to pursue clinical research and development
2001
Biocon becomes the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule
Biocon's proprietary bioreactor, PlaFractor™ is granted a US 2001 and world-wide patent
2002
Clinigene's clinical laboratory is the first in India to receive CAP accreditation
2003
Biocon is the first company worldwide to develop human insulin on a Pichia expression system
2004
Biocon creates a buzz in the stock market in March 2004 with its hugely successful IPO. Day 1 on the bourses closes with a market value of $1.11 billion, making Biocon only the second Indian company to cross the $1 billion mark on the first day of listing.
Syngene establishes new research centre
Biocon Limited, announces the launch of INSUGEN®, the new generation bio-insulin, manufactured in Asia's largest human insulin plant.
Biocon Limited and Vaccinex, Inc. announce a broad strategic partnership to discover and co-develop at least four therapeutic antibody products.
2005
Biocon signs a commercial agreement for supply of insulin API to Asia, Africa and the Middle East.
2006
Biocon inaugurates Biocon Biopharmaceuticals, India's largest multi-product Biologics facility at Biocon Park
Biocon inaugurates Biocon Park, India's largest integrated biotechnology hub, comprising an integrated cluster of research laboratories and manufacturing facilities spread across 90 acres in KIADB (Karnataka Industrial Areas Development Board) industrial estate.
Biocon announces a licensing agreement with Bayer HealthCare (BHC) for the exclusive marketing and trademark rights for INSUGEN® for the Chinese market.
Syngene and Innate Pharmaceuticals AB, Umea, Sweden conclude a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.
Biocon launches India's first anti-cancer drug BIOMAb EGFR™.
2007
Biocon and Abu Dhabi based pharmaceutical company Neopharma sign an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).
Biocon grants exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR™ in Pakistan.
Biocon announces the launch of its Nephrology Division and a comprehensive portfolio of renal therapy products.
Syngene enters into a research partnership with Bristol-Myers Squibb and completes the ground breaking ceremony of new research facility at Biocon Park.
Biocon signs Memorandum of Understanding with Deakin University, Australia. To establish Deakin Research Institute in Bangalore
Biocon divests enzymes division for USD 115 million to Novozymes. Biocon business portfolio to focus on biopharmaceuticals
Biocon and Abraxis BioScience, announce an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union.
Biocon and Neopharma sign an MOU to establish Neobiocon, a joint venture company in Dubai's biotechnology and research park, Dubiotech.
Biocon and Abraxis BioScience,Inc announce a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf countries.
Biocon presents the results of Phase 1 studies on its oral insulin product, IN-105 at the European Association for Study of Diabetes (EASD) meeting held at Amsterdam. Phase 1 studies were conducted on healthy volunteers who have been administered IN-105 in the form of a tablet. The human clinical data on IN-105 was presented at the session on Novel therapies. Based on these promising results, Biocon intends to now develop this molecule through further clinical trials.
Biocon and Abraxis BioScience, Inc. announce the approval to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer by the country's Drug Controller General. Commercial introduction of ABRAXANE in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.
Since its establishment, Biocon Foundation opened four Arogya Raksha Yojana primary healthcare clinics. Biocon Foundation established a cancer hospital along with Dr. Devi Shetty of Narayana Hrudayalaya
2008
Biocon acquires a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million
Biocon launches a Safety Device in the form of pre-filled syringes for two of its life saving products, GCSF (granulocyte-colony stimulating factor) and EPO (Erythropoietin) in collaboration with Safety Syringes Inc. ERYPRO Safe™ and NUFIL Safe™ are the first two drugs that will marketed using this novel device with other injectable products to follow in the future.
Biocon and Abraxis Bioscience launch ABRAXANE in India for treatment of Breast Cancer.
Biocon is ranked among the top 20 global biotechnology companies (Med Ad News).
Biocon is the 7th largest biotech employer in the world (Med Ad News).
Biocon announced the results of an ascending dose study on its oral insulin drug (IN-105) at the European Association for the Study of Diabetes (EASD) meeting in Rome. The study involved dosing Type 2 diabetes subjects with single doses of 0 mg (placebo), 10 mg, 15 mg, 20 mg and 30 mg tablets of IN-105 in 5 separate periods before a mixed 600 kcal breakfast. The outcome measurements were the safety and tolerability of IN-105, as well as the pharmacokinetics and pharmacodynamics of IN-105. The results showed that IN-105 was safe and well tolerated by patients.
NeoBiocon and Abraxis Bioscience launch Abraxane in The UAE for the treatment of Breast Cancer.
2009
Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon ParkAWARDS
Kiran Mazumdar-Shaw has received several awards on behalf of Biocon and in her personal capacity as one of India's leading business entrepreneurs. Biocon: 2009
Biocon's BIOMAb EGFR™ wins "Product of the Year",
BioSpectrum Awards
Biocon wins prestigious 2009 BioSingapore Asia Pasific Biotechnology Award for Best Listed Company
Biocon bags IDMA "Best Patent of the year" award
2008
Biocon is ranked among the top 20 global biotechnology companies (Source: Med Ad News, June 2008)
Biocon is the 7th largest biotech employer in the world (Source: Med Ad News, June 2008)
2007
Syngene receives "BioServices Company of the Year", BioSpectrum Awards
Biocon's BIOMAb EGFR™ wins "Product of the Year",
BioSpectrum Awards 2006
Best IT User Award in the Pharmaceutical Sector, NASSCOM 2004
India's first and No. 1 biotech company with a global ranking of 16* (Source: Biospectrum July 2004)
Biocon in India's top 5 Life Sciences companies (at close of trade as on July 30, 2004)
Best Reinvention of HR Function Award, Indira Group, Mumbai
Best Employer Of India Award, Hewitt
2003
Bio-Business Award for bio-entrepreneurship, Rabo India
Express Pharma Pulse Award for excellence in the
pharmaceutical industry
2001
Biotech Product, Process Development and Commercialisation Award, Department of Biotechnology, Ministry of Science and Technology, Government of India
2000
Technology Pioneer Recognition, World Economic Forum 1985
Export Performance Award, Karnataka State Financial
Corporation (KSFC)
National Award for Best Small Industry, Government of India
Kiran Mazumdar-Shaw: 2009
Honoured with 'Express Pharmaceutical Leadership Summit Award 2009' for Dynamic Entrepreneur
2008
Honorary Degree of Doctor of Science from the Heriot-Watt University, Edinburgh
Honorary Degree of Doctor of Science from the University of Glasgow
2007
Honoured with the, 'Veuve Clicquot Initiative For Economic Development For Asia' award
Honorary Doctor of Technology, University of Abertay, Dundee ( UK )
2005
Padmabhushan Award , one of India's highest civilian honours, from the President of India, Dr. APJ Abdul Kalam
Honorary Degree of Doctor of Science (Honoris Causa) from Indian Institute of Technology, RoorkeeThe Indian Chamber of Commerce Lifetime Achievement Award
Honorary Doctorate from Manipal Academy of Higher Education (MAHE), in recognition of outstanding achievements in biotechnology and industrial enzymes
Rotary Award for Corporate Citizenship
Business Leader of the Year Award - Biotechnology,
Chemtech-Pharma Bio Awards
2004
Honorary Doctorate of Science from Ballarat University, in recognition of pre-eminent contribution to the field of biotechnology
Business Woman Of The Year Award, The Economic Times 2003
Alumni High Achiever Award, Australian Alumni Association
2002
Karnataka Rajyotsava Award for pioneering biotechnology in India, the Government of Karnataka
Best Entrepreneur: Healthcare & Life Sciences Award,
Ernst & Young
Sir M. Visvesvaraya Memorial Award for contribution
to biotechnology, Federation of Karnataka Chambers
of Commerce & Industry (FKCCI)
1999
Woman of the Year Award, International Women's
Association, Chennai
1998
Golden Jubilee Felicitation, Mount Carmel College, Bangalore
1989
Padmashri for pioneering biotechnology in India,
Government of India 1987
Outstanding Young Person Award, Jaycees India 1983
Best Small Scale Industry in Karnataka Award,Rotary Club, Karnataka
Best Model Employer Award, Rotary Club, Karnataka
Outstanding Contribution Award, AWAKE
1982
Best Woman Entrepreneur Award, National Institute of
Marketing Management, India Strategic Alliances
Syngene partners with Sapient Discovery to expand integrated drug discovery offerings
SYNGENE - SAPIENT DISCOVERY: 2009
Syngene will offer fully integrated drug discovery services by partnering with Sapient Discovery, a US based Biotechnology Company located in San Diego. The companies intend to provide a highly integrated platform for structure-based drug discovery as a one stop shop for structure-guided discovery, chemistry, biology and structural biology capabilities.
About Sapient Discovery
Sapient Discovery is an established leader in structure-guided drug discovery with a number of proprietary algorithms and capabilities for efficient protein structure based drug discovery and optimization. Sapient Discovery's proprietary Genes-to-Leads, Fragments-to-Leads; and X-ray crystallography technologies provide dramatic reductions in the time and costs associated with compound synthesis and screening and expands the horizons of chemical diversity potentially applicable to novel or even well studied drug targets.
Acquisition for the marketing and distribution of a range of pharmaceuticals in Germany and Europe.
BIOCON-AXICORP 2008
Biocon reached an agreement to acquire a 70% stake in German pharmaceutical company, AxiCorp GmbH for a consideration of €30 Million. This will enable the marketing and distribution of a range of pharmaceuticals including generics, biosimilars, biologics and innovative pharmaceutical products in Germany and Europe. AxiCorp is a specialized marketing and distribution company established in 2002 by a group of industry experts to address the lucrative generics and parallel distribution market in Germany and Europe. AxiCorp is now an autonomous subsidiary of Biocon.
About AxiCorp
Established in 2002, AxiCorp is headquartered in Friedrichsdorf, (near Frankfurt) Germany and markets parallel distributed EU-pharmaceuticals as well as its own generic brand "axcount". This unique business approach contributes to significant cost savings for German health providers and patients in the patented pharmaceuticals market as well as in the off-patent market. AxiCorp is amongst the fastest growing pharmaceutical companies in Germany, with a turnover of €75 Million in 2007. Today, the company employs about 170 employees and has launched more than 180 products.
Partnership for the co-development of immunoconjugates for targeted immunotherapy of cancers and infectious diseases
BIOCON- IATRICa, 2008
Biocon Limited and IATRICa, Inc. announced a strategic partnership to co-develop an exclusive new class of immunoconjugates for targeted immunotherapy of cancers and infectious diseases. The companies will co-develop candidate products based upon IATRICa’s technology platform and Biocon’s proven expertise in drug development, biologics manufacturing, and clinical research.
About IATRICa Inc.
IATRICa is a privately held biotechnology company engaged in the discovery and development of novel targeted immunoconjugates for prevention or treatment of cancer and infectious disorders. IATRICa is a start-up company formed in 2007 with technology developed at the Johns Hopkins University, Baltimore, Maryland, USA, and has exclusive licenses to the immunoconjugate technology invented by Johns Hopkins scientists and company founders, Dr. Atul Bedi and Dr. Rajani Ravi. The company is headquartered in Baltimore, Maryland, USA.
Licensing agreement for G CSF in North America and the European Union & for the commercialisation of ABRAXANE in India
BIOCON-ABRAXIS: 2007
Biocon and Abraxis BioScience, Inc. have announced an agreement wherein Abraxis will license the right to develop a biosimilar version of G-CSF (Granulocyte-Colony Stimulating Factor) in North America and the European Union. Under the terms of the agreement, Biocon will receive an upfront licensing fee and, following approval in the licensed territories, royalties from Abraxis BioScience.
In addition, Biocon and Abraxis BioScience, Inc. have also announced a licensing agreement for the commercialization of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India. Under the terms of the agreement, Biocon will also have the right to market ABRAXANE in Pakistan, Bangladesh, Sri Lanka, United Arab Emirates, Saudi Arabia, Kuwait and certain other Persian Gulf countries. As part of this agreement, Abraxis will receive royalties from Biocon based on net sales of ABRAXANE in these countries.
Progress: Drug Controller General of India (DCGI) approval has been obtained to market ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer.
Commercial introduction of ABRAXANE in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical company dedicated to meeting the needs of critically ill patients. The company develops, manufactures and markets one of the broadest portfolios of injectable products and leverages revolutionary technology such as its nab™ platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life-threatening diseases. The first FDA approved product to use this nab platform, ABRAXANE®, was launched in 2005 for the treatment of metastatic breast cancer.
Partnership for Greater Focus in Biotechnology and Biosciences Research
BIOCON- DEAKIN UNIVERSITY: 2007
Biocon signed a Memorandum of Understanding with Deakin University for cooperation in the following areas:
-Establishment of the Deakin Research Institute in Bangalore.
-Joint development of a mammalian cell bio-processing
facility at Geelong, Victoria, Australia.
Deakin University, Victoria is Australia's fastest growing university in multi- disciplinary research with greater focus in biotechnology and biosciences research.
Partnership for research discovery and development in India
SYNGENE- BRISTOL-MYERS SQUIBB: 2007
Syngene has entered into a research partnership with Bristol-Myers Squibb (BMS). Through this symbiotic global partnership, Syngene will provide BMS research and development services for discovery and early drug development.
Exclusive Marketing License for BIOMAb EGFR™ for Pakistan
BIOCON-FEROZSONS: 2007
Biocon has granted an exclusive license to Ferozsons Laboratories Limited for marketing BIOMAb EGFR™ in Pakistan. The successful debut made by BIOMAb EGFR™ in the Indian market since mid-September, 2006, has evinced strong licensing interest for the proprietary cancer drug in the region. Biocon's decision to select Ferozsons Laboratories Limited as its exclusive licensee in Pakistan was based on the leadership position that the company enjoys in Oncology.
Ferozsons Laboratories Limited is the foremost national Oncology company in Pakistan.
Partnership to Manufacture and Market Biopharmaceuticals in GCC Countries
BIOCON- NEOPHARMA: 2007
Biocon and Abu Dhabi based pharmaceutical company Neopharma have signed an MOU to establish a JV to manufacture and market a range of biopharmaceuticals for the GCC countries (Gulf Cooperation Council).
This landmark agreement between the two companies heralds the region's first foray to develop and market life saving biopharmaceutical products.
Partnership to Develop Virulence Blockers
SYNGENE - INNATE PHARMACEUTICALS: 2006
Syngene and Innate Pharmaceuticals AB, Umea, Sweden concluded a cooperation agreement to jointly develop, manufacture and market virulence blockers to counteract bacterial diarrhoeal disease.
Progress: Using in vitro and cell-based assays, several novel small molecule inhibitors of Type 3 secretion in Yersinia and Salmonella have been identified in this collaboration. These promising inhibitors have been characterised for drug-like properties and analogs of such compounds are being synthesized in order to improve both potency and physico-chemical properties. Some of the promising compounds are now being tested in animal models for diarrhoea and evaluated for pharmacokinetics and toxicity profile in rodents.
Innate Pharmaceuticals AB was formed in 2000 to create a commercial platform for the world-leading research taking place at Umeå University and Karolinska Institute in Stockholm.
Licensing Agreement to Develop and Market Intranasal Insulin Spray
BIOCON-BENTLEY: 2005
Biocon signed a product licensing agreement with Bentley Pharmaceuticals, Inc. for its intranasal spray formulation for Insulin administration. The license agreement covers 85 countries, granting Biocon exclusive as well as co-exclusive rights to develop and market throughout Asia, Africa, and the Middle East.
In addition Biocon also entered into a long term supply agreement with Bentley. We will provide Bentley and its licensees, with a competitive supply of Insulin for worldwide markets. The terms of agreement assures Bentley commercial supply of Insulin for worldwide markets.
Progress: In 2007, Bentley received approval from the Drug Controller General of India (DCGI) to proceed with a Phase II clinical evaluation of Nasulin in Type II diabetic patients.
Bentley Pharmaceuticals Inc. , a technology-based specialty pharmaceutical and drug delivery company with a growing branded and generic product line in Europe.
Collaboration in Research and Research-Education
BIOCON-KAROLINSKA INSTITUTE: 2005
Biocon signed a Memorandum of Understanding (MOU) with the Karolinska Institute, Sweden to collaborate in research and research-education initiatives.
The agreement outlines the following areas of collaboration:
- Partnering in product development
- Joint PhD studies at Karolinska Institute
- Joint research programs between Karolinska Institute and Biocon
- Scientific symposia in India sponsored by Biocon in association with Karolinska Institute
Progress
- Mr. Shrikumar Suryanarayan, President, R&D Biocon Ltd
has been appointed honorary visiting faculty in the department of Molecular Medicine, Karolinska Institute.
- Joint Ph.D. programs are being conducted.
- In 2006, Madras Diabetes Research Foundation (MDRF)
and Karolinska Institute of Sweden organized a diabetes symposium. Biocon was a co-sponsor.
Karolinska Institute is Sweden's leading medical university, reputed to be among Europe's best. The institute's reputation for visionary science has afforded it the exceptional honour and responsibility to nominate The Nobel Prize for Medicine and Physiology every year.
Partnership to Discover and Develop Therapeutic Antibodies
BIOCON-VACCINEX: 2004
Biocon and Vaccinex, Inc. have embarked on a broad, strategic partnership to discover and co-develop fully humanized antibodies focused on cancer, inflammation and autoimmune diseases. The collaboration combines Vaccinex's unique capabilities to discover fully human monoclonal antibodies using its proprietary antibody discovery technology and Biocon's proven expertise in clinical research and biologics manufacturing.
Progress: Currently, two monoclonal antibodies, BVX-10 (directed against TNFa- a promising target for therapeutic intervention in Rheumatoid Arthritis) & BVX-20 (intended for use in the treatment of patients with relapsed or chemotherapy resistant follicular B-cell NHL and CD20 positive diffuse large B- cell NHL in combination with chemotherapy) have moved into preclinical stages.
Vaccinex is a privately held biotechnology company headquartered in Rochester, New York engaged in the discovery and development of novel therapeutic antibodies.
Partnership for the Co-development of Immunotherapy & Monoclonal Antibodies
BIOCON-CIMAB: 2003
Anticipating the increasing importance of immunotherapy
medicines of the future, Biocon established Biocon Biopharmaceuticals Pvt. Ltd. (BBPL), a joint venture with the Cuban Institute CIMAB to develop and market a range of MAbs and Cancer Vaccines. BBPL will benefit from CIMAB expertise in developing and manufacturing immunotherapy products (which today is largely imported into India) and Biocon's R&D and state-of-the-art manufacturing capabilities.
Progress: Launch of India's first anti-cancer drug, BIOMAb-EGFR™.
CIMAB is the commercial branch of the Center of Molecular Immunology (CIM), a Cuban biotechnology institution dedicated to research, product development and manufacture of mammalian cell culture products.
Quality
Quality Highlights
- An impressive track record in filing regulatory documents
in CTD (Common Technical Documents) format, worldwide
- DMF's for API's
- Dossiers for human insulin formulations, veterinary
products, oral dosage forms and parenterals
- Registration of our products in Europe through Mutual
Recognition Procedures and Decentralised Procedures (DCP)
- Approval for our products and testing facilities by the
Indian State and Central Drug Control Authorities
- DCGI accreditation for our QC laboratory as an approved
test house
For the period between April 2006 and March 2007 Biocon has undergone 41 successful compliance audits by various national and international customers and regulatory authorities.
| History |
|
|
|
Posted by
stockguru
at
8:55 AM
| | Profile | | | | | | Amongst the various reasons behind BSL's unprecedented growth and rapid integration on the steel value chain, perhaps, the most important would be its unwavering focus on acquiring the latest technology and know-how. The most important reason behind this focus has been BSL's commitment to provide its customers with the best quality products. The result, to say the least, has been awe-inspring growth. | | | | | The Khopoli plant, commissioned in 2004 has been playing a remarkable role not only in the growth of exports, but in the production of a much wider variety of value added steel like Colour Coated Sheets, High Tensile Steel Strappings, Hardened and Tempered Strips and Precision Tubes. In addition to these, the Khopoli plant has recently launched the Galume value added steel (Aluminium & Zinc Coated Sheet) for the first time in the country. | | | | | | | | | | Operating with the most advanced technology, expressed through a large fleet of latest equipment, machinery and systems, the Khopoli plant has given a tremendous boost of 425000 MT per annum to BSL's total production capacity Including 240000 MT of galvanised steel, which are further forward integrated into Colour Coated Sheet, Galume and other value added products. | | | | | Giving a tremendous volume-thrust to the production capacity of BSL is its plant at Sahibabad, with a production of 475,000 MT per annum comprising products such as Automotive Grade C R Sheet and Galvanised Sheets. | | | | | As a strategic move to optimise the usage of resources and services, as well as to streamline the functioning of all systems and process within the organisation, BSL has recently implemented SAP (the global leader in Enterprise Resource Planning Systems). After all, with sales touching Rs. 3070 crores and installed capacity in the one million tonnes per annum range, BSL is now India's 3rd largest Secondary Steel Producer after SAIL and TISCO. BSL has the distinction of being the only producer In India of the widest width CR Sheet, besides being a preferred supplier of automotive grade steel sheets for inner and outer panels to all leading 4-wheeler and 2-wheeler manufacturers in the country. | | | | | The most brilliant milestone in BSL's journey of excellence is the setting up of a state-of-the-art Hot Rolling Steel & Power Plant in Orissa. This Integrated Steel and Power Plant will, no doubt, put BSL firmly on the fast track of progress. | | | | | | Bhushan Steel Limited, is an ISO 9002,QS 9000 certified and a company of Rs. 2868 crores ($650 million approx.). | | | | | | As one of the prime movers of the Technological Revolution in the Indian Cold Rolled Steel Industry, BSL has emerged as the country’s largest and the only CR steel plant with an independent line for manufacturing Cold Rolled coils and sheets up to a width of 1700 mm, as well as Galvanised Steel Coils & Sheets up to width of 1350mm. | | | | | | The Company currently has capacity to produce ALMOST ONE MILLION MT/Annum of Cold Rolled Steel at Sahibabad and Khopoli Works . | | | | | | The Company is a “single-point source” for a wide variety of products such as CRCA , Galvanized and Colour coated sheets, High tensile steel ttrapping, Hardened and tempered steel strips (HTSS) and Precision tubes. | | | | | | | | | | | | | Mill Clean System With A Synthetic Coolant To Avoid Any Coolant Mark On The Strip | | | | | Electrolytic Cleaning Line To Remove Iron Fines From Strip , Which Helps In Improving The Life Of Salt – Spray Test After Painting And Avoids Carbon Soot Completely . It Also Increases The Tool Life In Press Shop | | | | | Latest And Sophisticated Edt Machine To Provide Controlled Texture For Better Paint Adhesion And To Achieve Surface Roughness To Close Tolerances | | | | | On- Line Tension – Levelling Equipment For Better Flatness And Controlled Elongation | | | | | | Computerized Inventory Control Management And Independent Skin- Pass Mill To Avoid Any Unwanted Storage In Between Annealing And Skinpass Process. | | | | | Kathabar Storage System ” To Avoid Atmospheric/Rustiness Oxidation Through De-Humidified Air.. | | | | | Electro - Static Rust Preventive Oil Spray System For Controlled Oil Coating On Crca Surface . Oil Coating Can Be Maintained In Between 0.50 Gms/M² To 2.00 Gms/M² Per Side. | | | | | EXCELLENT MECHANICAL PROPERTIES | | | | | Practically , No Variation In Mechanical Properties Due To 100 % Hydrogen Annealing Furnace | | | | | | The Raw Material Selection Is Done By Computerized Program For Different Applications | | | | | Close Tolerances On Thickness, Width And Length | | | | | - X- Ray Thickness Gauge To Measure Thickness To A Fraction Of A Micron. | | | - Radiometrie Thickness Checking Across The Width | | | - Automatic Computerized Thickness Control.. | | | - Shim Less Tooling On Slitting Lines With Computerized Setting Ensures Correct Width In Close Tolerances . | | | - Precision Cut- To – Length Lines To Ensure Length Tolerances Better Than 0.75 Mm. | | | - Automatic Electromagnetic Stacker On Shearing Lines To Produce Scratch Free | | | |
| | Chairman's Speech | | | | | | As one of the leading initiators of the technological revolution in the Indian steel industry, BSL's infrastructure, equipment and machinery are well-complemented by its people and continue to create benchmarks for the industry. | | | | | | | | | Bhushan Steel Ltd. (BSL) is in the process of setting up one of the most advanced Hot Rolling Plants of the world in Orissa. The construction of the first phase is being carried out with speed and is nearing completion. Together with its state-of-the-art Cold Rolling Plant at Sahibabad and another one at Khopoli, the company is well poised in the industry. The company has recently launched Galume, zinc and aluminium coated sheet, for the first time in India. Thereby, it is all set to revolutionise the industry and demand patterns.
Be it specialised steel for the automotive and white goods industry, or steel for highly discerning international clients, BSL's advanced manufacturing facilities and stringent quality standards have earned appreciation and acceptance in international markets. | | | | | | | | BSL is currrently exporting to Europe, USA, Canada, Africa, China and the Middle East, in addition to the Asian markets. And, is eagerly looking ahead, steadily defining the future of steel day by day. |
| Vision | | | | | | Giving Definition To A Far-sighted Vision | | | | | | | | The vision of evolving into a totally integrated steel producer, committed to achieving the highest standards of quality through cutting-edge technology, is being realised at Bhushan Steel Ltd. | 
Neeraj Singal
Managing Director | | | | | | | | If you can anchor your organisation with a single-mindedness of purpose, for providing-the best service, technology and quality to customers and stakeholders, then you can deliver higher value for money wrthin schedule and budget, and continue to thrive even in the face of rapid change and other challenges besotting the Indian economy and especilly the steel industry.
This is, precisely, what BSL has been doing since its inception: Acquiring the latest technology sourced from the global leaders and maintaining global quality standards; continually upgrading the steel plants and efficiently implementing projects within schedule and budget always meeting financial obligations on time and yes, these are the hallmarks of BSL's Saga of Excellence.
| | | | | | | | | | | BSL's vision of total integration is a lot closer to realisation today. Through seamless backward integration, BSL is consolidating its position on the entire steel value chain - from iron ore to specialised, value-added steel, the company is surging ahead. |
| Policies | | | | | | BHUSHAN STEEL LTD, SAHIBABAD | | | | | | | | Integrated Quality, Environment, Occupational Health & Safety Management System Policy | | | | | | | | Bhushan Steel Ltd. commits to produce cold rolled and galvanized steel sheets of world class quality in a safe, healthy and clean environment by involving employees with continual improvements in system implementation, technological advancement, operational integration, prevention of pollution & hazards maintaining | | | | | | | | | | | | Legal compliance and satisfying needs & expectations of Customers. | | | | | | | | - For Environmental Management System we have ISO 14001:2001 Certification
- For Quality System we have ISO/TS 16949:2002 Certification
- For Safety Management System we have OHSAS 18001:1999 Certification
| | Recognition | | | | | | | ISO 14001 : 2004 | | ISO/TS/16949:2002 | | OHSAS 18001: 1999 | | | | | | | | | | | | | |  | |  | |  | | | |
|
| | |
| | |
| |
Board of Directors | | | | Technical Supports | | | Shri Brij Bhushan Singal | | Chairman | | | Shri Neeraj Singal | Managing director |
|
|
